How Big is the Cell And Gene Therapy Market?

The global cell and gene therapy market size reached US$ 18.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 60.1 Billion by 2032, exhibiting a growth rate (CAGR) of 15.66% during 2024-2032.

Factors Affecting the Growth of the Cell and Gene Therapy Industry:

• Technological advancements:

Technological advancements have played a crucial role in propelling the cell and gene therapy market forward. The advent of advanced techniques like CRISPR-Cas9, zinc finger nucleases (ZFNs), and transcription activator-like effector nucleases (TALENs) have revolutionized the field by enabling precise modifications to the genetic material of cells. CRISPR-Cas9, in particular, has emerged as a powerful tool due to its simplicity, efficiency, and versatility, allowing researchers to edit genes with unprecedented precision. Moreover, improvements in viral and non-viral vectors for delivering therapeutic genes into target cells have significantly enhanced the efficacy and safety of gene therapy treatments, creating a positive outlook for market expansion.

• Increasing investment:

Another major driver of the cell and gene therapy market is the substantial increase in investment from both the public and private sectors. Pharmaceutical companies, biotechnology firms, and venture capitalists are pouring significant resources into research and development efforts aimed at advancing cell and gene therapies. This influx of funding has accelerated the translation of promising preclinical findings into clinical applications, leading to a growing pipeline of cell and gene therapy candidates across various therapeutic areas. Additionally, government initiatives and regulatory support have bolstered investment in the field. Funding agencies, such as the National Institutes of Health (NIH) in the United States and the European Commission's Horizon 2020 program, provide grants and incentives to support innovative research in cell and gene therapy, thereby aiding in market expansion.

• Growing demand for personalized medicine:

The increasing demand for personalized medicine is driving the adoption of cell and gene therapies, particularly in the treatment of genetic disorders and cancer. Unlike conventional pharmaceuticals, which often provide one-size-fits-all solutions, cell and gene therapies have the potential to be tailored to individual patients based on their genetic makeup and disease characteristics. This personalized approach enhances treatment efficacy and safety while minimizing adverse effects. Furthermore, advancements in biomarker identification and diagnostic technologies have enabled clinicians to select suitable candidates for cell and gene therapy interventions and monitor treatment responses more effectively. As a result, patients and healthcare providers are increasingly seeking innovative therapeutic options that offer personalized solutions and improved clinical outcomes.

Request For a PDF Sample Report: https://www.imarcgroup.com/cell-gene-therapy-market/requestsample

Cell and Gene Therapy Market Report Segmentation:

Breakup by therapy type:

• Cell Therapy
  • Stem Cell
    • Pluripotent Stem Cell
    • Cancer Stem Cell
    • Adult Stem Cell
  • Non-Stem Cell
    • T Cells
    • Natural Killer
    • Others
• Gene Therapy

Based on the therapy type, the market is segmented into cell therapy (stem cell (pluripotent stem cell, cancer stem cell, and adult stem cell) and non-stem cell (T cells, natural killer, and others)) and gene therapy.

Breakup by Indication:

• Cardiovascular Disease
• Oncology Disorder
• Genetic Disorder
• Infectious Disease
• Neurological Disorder
• Others

Oncology disorders dominate due to the potential of gene therapy to target specific cancer types effectively.

Breakup by Delivery Mode:

• In-Vivo
• Ex-Vivo

Based on the delivery mode, the market is divided into in-vivo and ex-vivo.

Breakup by End User:

• Hospitals
• Cancer Care Centers
• Pharmaceutical & Biotechnology Companies
• Others

Hospitals lead as end users due to their infrastructure and capacity to administer complex cell and gene therapies.

Market Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America leads in the cell and gene therapy market due to its advanced healthcare infrastructure, supportive regulatory environment, and significant investment in research and development.

Global Cell and Gene Therapy Market Trends:

The increasing prevalence of rare genetic diseases and chronic disorders, coupled with the expanding understanding of the genetic basis of diseases, is providing an impetus to the market. Additionally, the rising demand for innovative treatment modalities with the potential for long-term efficacy and disease modification is aiding in market expansion. Furthermore, the growing trend towards value-based healthcare and the shift from traditional treatment models to more targeted and curative therapies are bolstering the market growth. Apart from this, advancements in manufacturing processes, such as automation and scalability, are reducing production costs and improving accessibility to these cutting-edge treatments, thereby propelling the market forward.

Leading Companies Operating in the Global Cell and Gene Therapy Industry:

• Amgen Inc.
• Biogen
• Bluebird bio, Inc.
• Bristol-Myers Squibb
• Gilead Science
• Kolon TissueGene Inc.
• Orchard Therapeutics plc.
• Pfizer Inc
• Renova Therapeutics
• Spark Therapeutics, Inc

Browse the full report with TOC and list of Figures: https://www.imarcgroup.com/cell-gene-therapy-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145